Early Evidence of Neratinib Benefit in HER2-Positive Metastatic Cervical Cancer
Single-agent neratinib was associated with durable responses in a subcohort of women in the SUMMIT trial.
Society of Gynecologic Oncology (SGO)
Racial Differences in Immune Escape Mechanisms of Ovarian Cancer
High expression of indoleamine 2.3-dioxygenase pathway genes correlated with the presence of immune escape mechanisms in ovarian cancers, according to researchers.
Carboplatin Desensitization Associated With Improved Overall Survival in Recurrent Ovarian Cancer
The OS benefit of carboplatin desensitization was limited to the subgroup of women with recurrent ovarian cancer without deleterious germline BRCA1/2 mutations.
Evaluating Chemotherapy Plus Adjuvant Radiation Therapy for Vulvar Cancer
Researchers found that adjuvant chemoradiation therapy was preferable over adjuvant radiation therapy alone for squamous cell carcinoma of the vulva.
Maintenance Olaparib May Be More Cost-Effective Than Bevacizumab in BRCA-Mutant Ovarian Cancer
Researchers estimated cost effectiveness for first-line maintenance therapy with bevacizumab or olaparib in women with BRCA-mutant ovarian cancer.
Pembrolizumab, Bevacizumab, Cyclophosphamide Combination for Ovarian Cancer: Promising Phase II Results
Tumor response rates were higher in patients with platinum-sensitive recurrent ovarian cancers, according to researchers
Social and Financial Assistance Programs to Overcome Barriers for Patients With Cervical Cancer
According to researchers, the prevalence of HPV-16 infection in a cohort of young women in Japan decreased from 1.3% in 2014 to 0% in 2017.
HPV Vaccination Influences Prevalence of Type-Specific HPV Infection
According to researchers, the prevalence of HPV-16 infection in a cohort of young women in Japan decreased from 1.3% in 2014 to 0% in 2017.
Racial Disparities in the Use of Brachytherapy to Treat Cervical Cancer
Black women with locally advanced cervical cancer are significantly less likely to receive brachytherapy compared with non-black women with this disease.
The Relationship Between Niraparib Dose Reduction and Efficacy in Ovarian Cancer
In the QUADRA trial patients with low baseline platelet count or low body weight were more likely to experience grade 3/4 adverse events.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...